GSK Bets Over $745 Million on Highly Selective, First-in-Class siRNA EMP-012 for COPD

October 28, GSKAnnounced with Empirico that they have reached a global exclusive license agreement for EMP-012.

Screenshot source: Corporate official website

EMP-012 is aHighly Selective First-in-Class siRNA, and is expected to becomeBest-in-class siRNA, is an oligonucleotide. EMP-012 targets a completely new therapeutic target and is currently under development for the treatment of chronic obstructive pulmonary disease (COPD).(COPD) ThePhase I ClinicalIn the experimental stage, with the hope of expanding to other inflammatory respiratory diseases.

Thanks to Empirico's proprietary siRNA chemical technology, EMP-012 demonstrates potent efficacy and a longer dosing interval, aligning with GSK's ongoing COPD program.(Including long-acting biologics)Forming a strategic complement. In addition to its potential as a monotherapy, EMP-012 also provides GSK with more options for combination therapies within its COPD portfolio and pipeline.

According to the agreement, GSKWill Pay$85 millionThe advance payment and up to$660 millionBased on successful development, regulatory and commercial milestone payments, as well as tiered royalties on global net sales.